Anther Keung, PhD, RPh

VP Clinical Pharmacology

Dr. Keung serves as the Vice President of Clinical Pharmacology at Boston Pharmaceuticals. With over 25 years of experience in the pharmaceutical and biotechnology industries, he has contributed to the development and commercialization of multiple innovative therapies in metabolic, hepatology, gastroenterology, oncology, and infectious diseases.

Prior to joining Boston Pharmaceuticals, Dr. Keung held the position of Head of Clinical Pharmacology at Pioneering Medicine, a business unit of Flagship Pioneering, and Head of Clinical Pharmacology at several biotechnology companies including Axcella, Arvinas, Cyclerion, and Ironwood Pharmaceuticals. Dr. Keung has authored multiple publications and holds several patents.

Earlier in his career, Dr. Keung held progressively senior roles at Johnson and Johnson, Bristol Myers Squibb, Merck, and Sanofi, where he was involved in all stages of nonclinical and clinical development, from early development to Phase IV studies. A pharmacist by training, he graduated from Northeastern University and received a PhD from at the University of Connecticut in Pharmaceutical Sciences. He is a registered pharmacist in the State of Massachusetts.

Dr. Keung’s industry experience also includes leading teams across multiple regions, including emerging markets, where he has assessed business and competitive landscapes, managed clinical pharmacology, drug metabolism and pharmacokinetic organizations, and developed regulatory strategies to advance product portfolios.

At Boston Pharmaceuticals, Dr. Keung leads strategic, scientific, and operational clinical pharmacology. He represents the department on strategic and operational cross-functional program teams and is responsible for the development of clinical pharmacology plans, assists in divisional management through program reviews and collaborative decision-making, mentors and guides colleagues, and co-leads programmatic and departmental initiatives. Dr. Keung plays a key role in advancing the clinical development of BOS-580 for treatment of MASH.